Malaysia has not directly accused North Korea of being behind the February 13 killing of Kim Jong Nam, but the statement from the Foreign Ministry comes hours after a North Korean envoy rejected a Malaysian autopsy finding that VX nerve agent killed Kim, saying the man probably died of a heart attack because he suffered from heart disease, diabetes and high blood pressure.
The statement from Malaysia's Foreign Ministry said it was "greatly concerned" with the use of the toxic chemical and condemned the use of such a chemical weapon under any circumstances.
The death of Kim, the estranged half brother of North Korea's ruler, has unleashed a diplomatic battle between Malaysia and North Korea. The autopsy is especially sensitive because North Korea had asked Malaysia not to perform one, but authorities said they had to under the law.
Also yesterday, amid growing fallout from the killing, Malaysia announced it is scrapping visa-free entry for North Koreans.
Malaysian officials say two women smeared VX nerve agent a banned chemical weapon on Kim's face as he waited for a flight at Kuala Lumpur's airport on February 13. Kim died within 20 minutes, authorities say. No bystanders reported falling ill.
Malaysia's autopsy finding that VX nerve agent killed Kim boosted speculation that North Korea orchestrated the attack. Experts say the oily poison was almost certainly produced in a sophisticated state weapons laboratory.
North Korea has denied any role and accused Malaysia of bias.
Yesterday, Ri Tong Il, a former North Korean deputy ambassador to the United Nations, told a news conference that it made no sense to say the two women used such a deadly toxin without also killing or sickening themselves and people around them.
"This is a strong indication that the cause of death is a heart attack," Ri said.
North Korea does not acknowledge that it was Kim Jong Nam who died. Instead, it refers to the victim as Kim Chol, the name on the diplomatic passport he was carrying. Malaysia has confirmed that the victim was Kim Jong Nam.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
